Zimberelimab  (Synonyms: 赛帕利单抗; GLS-010; AB-122; WBP-3055)

Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma^[1][2].

Human IgG4 lambda

Human

Zimberelimab 对人 PD-1 的 EC₅₀ 为 210 pM，但不结合相关的 CD28 家族受体，例如 ICOS、CD28 和 CTLA-4^[1]。
Zimberelimab 与细胞表达的人 PD-1 结合，抑制受体与人 PD-L1 和 PD-L2 的相互作用，IC₅₀ 分别为 580 pM 和 670 pM^{[1 ]}。
Zimberelimab 剂量依赖性地增强 CD4⁺ T 细胞的 IFN-γ 产生和增殖，在浓度低于 100 pM 时达到饱和^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Zimberelimab 对人 PD-1 的 EC₅₀ 为 210 pM，但不结合相关的 CD28 家族受体，例如 ICOS、CD28 和 CTLA-4^[1]。
Zimberelimab 与细胞表达的人 PD-1 结合，抑制受体与人 PD-L1 和 PD-L2 的相互作用，IC₅₀ 分别为 580 pM 和 670 pM^{[1 ]}。
Zimberelimab 剂量依赖性地增强 CD4⁺ T 细胞的 IFN-γ 产生和增殖，在浓度低于 100 pM 时达到饱和^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2259860-24-5

液体

Colorless to light yellow

赛帕利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 lambda

• 
  Immobilized PD-1 Protein (ECD, His Tag), Human can bind Zimberelimab. The EC₅₀ for this effect is 3.01 ng/mL.

• [1]. Markham A. Zimberelimab: First Approval. Drugs. 2021 Nov;81(17):2063-2068.  [Content Brief]

  [2]. Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955.  [Content Brief]